← Leaderboards
Gowthami M Arepally
Duke University
$11,531,413
Attributed
$13,676,032
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,676,032 · 11
By mechanism
R01$7,368,245 · 3
T32$2,760,057 · 1
P01$1,980,982 · 2
R21$874,500 · 2
K08$505,548 · 1
R03$157,000 · 1
Top collaborators
- Douglas Brock Cines6 shared
- Lubica Rauova6 shared
Most similar at Duke University
Same institution · by research overlap
- Douglas Brock Cines$21,888,352
- Thomas L Ortel$32,805,539
- Lubica Rauova$2,618,913
- Alisa S Wolberg$13,659,847
- Richard Clinton Becker$11,111,515
Others in their field
Top investigators on “Heparin”
- Thomas L Ortel · Duke University$23,256,763
- Mortimer Poncz · University Of Pennsylvania$22,311,527
- Umesh Ramanlal Desai · Versiti Blood Health, Inc.$11,929,621
- Douglas Brock Cines · Duke University$11,304,101
- Patricio Ernesto Ray · Children'S National Medical Center$11,000,597
- Erik Ian Tucker · Aronora, Inc.$10,952,616
Research focus
HeparinAntibodiesResponseLifeAntigensIn VivoComplexImmuneMediatingBaseIn VitroThrombocytopeniaPlatelet Factor 4Immune ResponseAntibody FormationSignal TransductionBlood PlateletsPharmaceutical PreparationsAnticoagulantsPathogenesisChargeCell SurfaceInsightThrombosis
Grant awards (47)
Complement and thrombosis in HIT$799,424
R01 · FY2025 · HL · contact PI
Hematology & Transfusion Medicine$278,524
T32 · FY2025 · HL · contact PI
Complement and Thrombosis in HIT$577,238
R01 · FY2024 · HL · contact PI
Hematology & Transfusion Medicine$503,190
T32 · FY2024 · HL · contact PI
Comparative studies of complement responses to ICs$201,250
R21 · FY2024 · AI · contact PI
2024 Hemostasis Gordon Research Conference and Gordon ResearchSeminar$29,700
R13 · FY2024 · HL · contact PI
Adrien Jacobs - Undergraduate Research Supplement 5R01-HL151730$11,978
R01 · FY2024 · HL · contact PI
Complement and Thrombosis in HIT$595,500
R01 · FY2023 · HL · contact PI
Hematology & Transfusion Medicine$482,790
T32 · FY2023 · HL · contact PI
Comparative studies of complement responses to ICs$241,500
R21 · FY2023 · AI · contact PI
Complement and Thrombosis in HIT$599,600
R01 · FY2022 · HL · contact PI
Hematology & Transfusion Medicine$275,406
T32 · FY2022 · HL · contact PI
Complement and Thrombosis in HIT$633,189
R01 · FY2021 · HL · contact PI
Complement and CR2/CD21 in the Immune Pathogenesis of HIT$464,233
R01 · FY2021 · HL · contact PI
Hematology & Transfusion Medicine$450,268
T32 · FY2021 · HL · contact PI
Complement and CR2/CD21 in the Immune Pathogenesis of HIT$544,393
R01 · FY2020 · HL · contact PI
Transfusion Medicine and Hematology$346,162
T32 · FY2020 · HL · contact PI
Complement and CR2/CD21 in the Immune Pathogenesis of HIT$515,562
R01 · FY2019 · HL · contact PI
Transfusion Medicine and Hematology$423,717
T32 · FY2019 · HL · contact PI
Administrative Supplement: Ayiesha Barnes$78,394
R01 · FY2019 · HL · contact PI
Complement and CR2/CD21 in the Immune Pathogenesis of HIT$477,000
R01 · FY2018 · HL · contact PI
Complement and CR2/CD21 in the Immune Pathogenesis of HIT$45,870
R01 · FY2018 · HL · contact PI
Immune Pathogenesis of HIT$317,114
P01 · FY2016 · HL · contact PI
Immune Pathogenesis of HIT$173,666
P01 · FY2015 · HL · contact PI
Immune Pathogenesis of HIT$157,182
P01 · FY2015 · HL · contact PI
Immune Pathogenesis of HIT$164,198
P01 · FY2014 · HL · contact PI
Immune Pathogenesis of HIT$164,194
P01 · FY2014 · HL · contact PI
Immune Pathogenesis of HIT$162,505
P01 · FY2013 · HL · contact PI
Immune Pathogenesis of HIT$162,501
P01 · FY2013 · HL · contact PI
Modeling the spectrum of HIT pathobiology$78,500
R03 · FY2013 · AI · contact PI
Immune Pathogenesis of HIT$339,811
P01 · FY2012 · HL · contact PI
Immune Pathogenesis of HIT$339,811
P01 · FY2012 · HL · contact PI
Clinical Significance of protamine/heparin antibodies after CPB$196,250
R21 · FY2012 · HL · contact PI
Modeling the spectrum of HIT pathobiology$78,500
R03 · FY2012 · AI · contact PI
Clinical Significance of protamine/heparin antibodies after CPB$235,500
R21 · FY2011 · HL · contact PI
Immune Dysregulation in HIT$340,821
R01 · FY2010 · HL · contact PI
Immune Dysregulation in HIT$340,821
R01 · FY2009 · HL · contact PI
Immune Dysregulation in HIT$294,009
R01 · FY2009 · HL · contact PI
Immune Dysregulation in HIT$19,250
R01 · FY2009 · HL · contact PI
Immune Dysregulation in HIT$340,821
R01 · FY2008 · HL · contact PI
Immune Dysregulation in HIT$340,548
R01 · FY2007 · HL · contact PI
Immune Dysregulation in HIT$349,594
R01 · FY2006 · HL · contact PI
PATHOGENESIS OF THROMBOSIS IN HIT$125,334
K08 · FY2003 · HL
PATHOGENESIS OF THROMBOSIS IN HIT$125,334
K08 · FY2002 · HL
PATHOGENESIS OF THROMBOSIS IN HIT$74,404
K08 · FY2001 · HL
PATHOGENESIS OF THROMBOSIS IN HIT$53,036
K08 · FY2001 · HL
PATHOGENESIS OF THROMBOSIS IN HIT$127,440
K08 · FY2000 · HL